Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Enantiomerically purified GPER agonist for use in treating disease states and conditions

Enantiomerically purified GPER agonist for use in treating disease states and conditions

US Patent 10934277 · Granted Mar 2, 2021

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Methods of using androgen receptor inhibitors as cancer therapeutics2024
Compositions and methods for decreasing, or preventing or reversing gain of, ski2024
Enantiomerically purified GPER agonist for use in treating disease states and co2023
Enantiomerically purified GPER agonist for use in treating disease states and co2023
Enantiomerically purified GPER agonist for use in treating disease states and co2023
Enantiomerically purified GPER agonist for use in treating disease states and co2023
Compounds, compositions and methods for prevention and/or treatment of cancer2022
Compositions and methods for decreasing, or preventing or reversing gain of, ski2022
Phosphaplatin liquid formulations2021
Solid state forms of a PDE10 inhibitor2018
Processes and intermediates for the preparation of a PDE10 inhibitor2017
Sodium channel modulators for the treatment of pain and diabetes2016